Remote patient monitoring increasingly popular, even as pandemic eases, analysis of insurance claims shows

Cardiologists are the main users of RPM devices, with blood pressure diagnoses accounting for more than half of all claims made in 2021. Diabetes, which accounts for 16% of claims, is the next most active area.

By Nick Paul Taylor • March 2, 2023

Lilly agrees to lower insulin prices by 70%

The pharma company, along with its diabetes drug rivals Novo Nordisk and Sanofi, has long been under pressure over the high cost of insulin — scrutiny that has recently ramped up in the U.S.

By Jonathan Gardner • March 1, 2023

Medtronic links MiniMed 780G automated insulin delivery to sustained glucose control benefits

The data indicates patients should receive automated insulin delivery earlier, rather than starting treatment with multiple daily injections, Medtronic said.

By Nick Paul Taylor • Feb. 27, 2023

Insulet exceeds sales forecast amid signs Omnipod 5 is winning share in diabetes pump market

The pump will be a “share taker for some time to come,” as patients switch from rival devices, said Insulet’s CFO.

By Nick Paul Taylor • Feb. 24, 2023

Tandem sees growth in new product launches after $95M loss on decline in pump placements

Craig Hallum analysts said 2022 was a “tough year” for Tandem but noted the company’s 2023 forecast should “properly” set expectations.

By Elise Reuter • Feb. 23, 2023

Apple makes strides in watch-based blood glucose tracking, Bloomberg reports

The company has been working on needle-free blood glucose tracking technology for 12 years, but has yet to show any meaningful clinical data, a J.P. Morgan analyst wrote.

By Elise Reuter • Feb. 22, 2023

Embecta raises 2023 earnings forecast after better-than-expected start

Almost a year after the company spun off from Becton Dickinson, CEO Dev Kurdikar said Embecta’s quarterly results “exceeded our initial expectations” in a challenging market.

By Elise Reuter • Feb. 15, 2023

Insulet pays Bigfoot Biomedical $25M for pump-based automated insulin delivery technology

Insulet framed the Bigfoot deal as a way to double its IP portfolio and strengthen its position in the insulin pump market.

By Nick Paul Taylor • Feb. 14, 2023

Dexcom secures Medicare coverage for G7 CGM with device set to launch this week

The decision by the CMS will include coverage for people with Type 1 and Type 2 diabetes who are on intensive insulin therapy.

By Elise Reuter • Feb. 13, 2023

Dexcom reports another record year of new customers amid continued demand for G6 device

The diabetes tech firm aims to keep boosting awareness of its CGMs with another Super Bowl commercial.

By Elise Reuter • Feb. 9, 2023

Abbott device approval sets up battle with Medtronic, Nevro for diabetic peripheral neuropathy treatment

Three firms are bringing their devices to a $3 billion to $5 billion market, aiming to relieve a painful side effect of diabetes.

By Elise Reuter • Feb. 6, 2023

Medtech earnings highlights: Easing of macro pressures, accelerated growth in 2023

Still, the latest round of quarterly results show that hospital staffing and supply chain remain a challenge.

By Nick Paul Taylor • Feb. 6, 2023

Friday Q&A: Tandem’s chief strategy officer talks tubeless pumps, Type 2 plans

Elizabeth Gasser also discusses the company’s recent acquisition of AMF Medical as well as how it factors environmental impact into device design.

By Elise Reuter • Jan. 27, 2023

Abbott sees ‘signs of stability’ for 2023 as hospital staffing, supply chain improves

While the company continues to grapple with supply shortages and procedure restrictions, it sold more COVID-19 tests than expected in the fourth quarter.

By Elise Reuter • Jan. 25, 2023

Insulet reports personal-data leak of 29,000 insulin pump customers

In a recall communication to users, Insulet shared information with its website performance and marketing partners through cookies and other trackers embedded in its website. 

By Nick Paul Taylor • Jan. 24, 2023

Diabetes outlook: What Dexcom, Medtronic and other leaders are watching in 2023

From new product launches to regulatory changes that could expand CGM coverage, company executives and analysts share their predictions.

By Elise Reuter • Jan. 20, 2023

Dexcom CEO discusses 2023 plans, expanding to more patients with Type 2 diabetes

MedTech Dive caught up with Kevin Sayer for a conversation about forthcoming product launches and long-term plans to expand CGMs to a broader group of patients. 

By Elise Reuter • Updated Jan. 20, 2023

How Abbott plans to make its Freestyle Libre a $10B product

CEO Robert Ford discussed plans to grow the market for Abbott’s continuous glucose monitors, and its broader diabetes strategy.

By Elise Reuter • Jan. 10, 2023

Beta Bionics hires Harvard diabetes expert as CMO ahead of artificial pancreas launch

Steven Russell has joined the company as chief medical officer, completing a new leadership team that began taking shape with the appointment of Sean Saint as CEO last year.

By Nick Paul Taylor • Jan. 10, 2023

Dexcom forecasts 2023 revenue to rise as much as 20% on G7 launch

Sales are expected to reach $3.35 billion to $3.49 billion for the full year.

By Elise Reuter • Jan. 9, 2023

‘Mea culpa’: What Goldman Sachs analysts got wrong about Medtronic in 2022

Medtronic has struggled to deliver on key projects in recent years, leading to a decline in its stock performance.

By Nick Paul Taylor • Jan. 4, 2023

As diabetes technology advances, blood glucose control declines: study

Mexican-American and non-Hispanic Black adults saw the greatest drop as the proportion of patients with glycemic control fell from 29.2% between 1988 and 1994 to 27.5% between 2013 and 2020.

By Nick Paul Taylor • Dec. 21, 2022

Novo Nordisk expands Amalgam Rx insulin app pact, plots integration with other devices

Supported by Novo Nordisk, Amalgam Rx will incorporate and integrate with connected insulin delivery devices, continuous glucose monitors and electronic health records.

By Nick Paul Taylor • Dec. 20, 2022

Dexcom’s Jake Leach discusses preparations for G7 launch next year

The diabetes tech company is in conversations with payers and is opening a new manufacturing plant ahead of the planned launch of its newest CGM, the COO said. 

By Elise Reuter • Dec. 15, 2022

Tandem agrees to buy AMF, challenging Insulet for insulin pump patch market

The deal will give Tandem control of Sigi, a reusable, rechargeable patch pump that is designed to be smaller and lighter than existing devices.

By Nick Paul Taylor • Dec. 14, 2022